Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745166 | 0.79 | APP (0.41) | APPCA2 | |
| SCHEMBL18030513 | 0.76 | APP (0.39) | APPCA2 | |
| SCHEMBL17277049 | 0.75 | APP (0.36) | APPCA2 | |
| SCHEMBL31207739 | 0.75 | APP (0.36) | APPCA2 | |
| SCHEMBL220873 | 0.74 | CA2 (0.61) | CA2 | |
| SCHEMBL220561 | 0.74 | CA2 (0.61) | CA2 | |
| SCHEMBL22566305 | 0.74 | APP (0.38) | APPCA2 | |
| SCHEMBL18485037 | 0.74 | APP (0.38) | APPCA2 | |
| SCHEMBL220562 | 0.74 | CA2 (0.61) | CA2 | |
| SCHEMBL31207727 | 0.74 | APP (0.35) | APPCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696707-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-10246478-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2019-04-02 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| EP-3156410-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-04-19 | — | — | EP | disclosed |
| EP-2252595-B1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-03-26 | — | — | EP | disclosed |
| EP-2252595-B1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8618290-B2 | HSP90 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-31 | — | — | US | disclosed |
| US-20120264770-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20090305998-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2113500-A1 | MAPK/ERK kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| EP-2089359-A2 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009097578-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | disclosed |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA CALIFORNIA, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008055236-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-08 | — | — | WO | disclosed |
| EP-0242482-B1 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1995-09-06 | — | — | EP | disclosed |
| US-4965270-A | Viricides | BEECHAM GROUP P.L.C. (GB) | 1990-10-23 | — | — | US | disclosed |
| EP-0298601-A1 | 6-Deoxy guanine derivatives and pyrimidine intermediates | BEECHAM GROUP PLC (GB) | 1989-01-11 | — | — | EP | disclosed |
| EP-0242482-A2 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305998-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | APP 2986/4885CA2 4094/4885 |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | APP 3032/4885CA2 4408/4885 |
| US-10246478-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | APP 3032/4885CA2 4408/4885 |
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | APP 3032/4885CA2 4408/4885 |
| US-20080188453-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | APP 2133/4885CA2 4124/4885 |
| US-20120264770-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | APP 2986/4885CA2 4094/4885 |
| US-10696707-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | APP 3032/4885CA2 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.